OmniAb's sales rose, it raised its 2026 sales outlook and cut expected costs, and it signed a Lilly licensing deal. Future milestone and royalty payments depend on program progress, so they are not assured.
The higher sales outlook and lower expected costs suggest OmniAb expects its business to improve. The Lilly deal adds a chance for later milestone and royalty income. Those payments depend on program progress, and the company expects cash flow to reach only break-even this year.
Lilly joined OmniAb on a new ion-channel discovery program, but the call reports no change in Lilly's sales, costs, or results from the program. It does not show a changed outlook for Lilly.
Follow OmniAb, Inc. (OABI) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for OABI